Email this article Efficacy of Cellex in patients with mild cognitive impairment
- Authors: Abusueva B.A.1, Evzel’man M.A.2, Kamchatnov P.R.3, Umarova K.Y.4
-
Affiliations:
- Dagestan State Medical Academy, Ministry of Health of Russia
- I.S. Turgenev Oryol State University, Medical Institute
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Medical Faculty, Chechen State University
- Issue: Vol 6, No 3 (2016)
- Pages: 17-23
- Section: LECTURES AND REVIEWS
- Published: 12.10.2016
- URL: https://nmb.abvpress.ru/jour/article/view/167
- DOI: https://doi.org/10.17650/2222-8721-2016-6-3-17-23
- ID: 167
Cite item
Full Text
Abstract
Background. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an effective measure. MCI detection and timely initiation of treatment in most patients is essential to delay the onset of severe dementia.
Objective. Investigating influence of Cellex in patients with chronic cerebral ischemia and MCI.
Materials and methods. As a part of non-interventional observational comparative study we evaluated the results of Cellex administration in 90 patients with MCI. Patients were divided into 2 groups. Patients from both groups received 1 course of 10 subcutaneous injections of Cellex drug at the dose of 1 mL, and patients from group 2 received two identical courses with an interval of two months. The survey, which included psychometric testing by using special questionnaires (Mini-Mental State Examination, “Frontal Assessment Battery” and “Clock Drawing” tests, Schulte test) was performed before treatment, and at months 1 and 2 after its completion.
Results. Neuropsychological examination revealed improvement in the patients state, more pronounced after the 2nd course of therapy.
Discussion. Our results provide a basis for using Cellex in patients with chronic cerebral ischemia and MCI, allowing to proceede with further studies on the optimal dosage of that drug.
About the authors
B. A. Abusueva
Dagestan State Medical Academy, Ministry of Health of Russia
Email: face@neicon.ru
Russian Federation
M. A. Evzel’man
I.S. Turgenev Oryol State University, Medical Institute
Email: face@neicon.ru
Russian Federation
P. R. Kamchatnov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Author for correspondence.
Email: face@neicon.ru
Russian Federation
Kh. Yu. Umarova
Medical Faculty, Chechen State University
Email: face@neicon.ru
Russian Federation
References
Supplementary files
